MarketInOut Stock Screener Log In | Sign Up

Biomea Fusion Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Biomea Fusion Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization46.24 mln
Float67.58 mln
Earnings Date11/03/2026

Piotroski F-Score

2 / 9
Weak

1-Year Forecast

6.17
Transformational upside

Relative Strength

4 / 100
Severely lagging

Debt / Equity

0.07
Debt-free

ROE

-157
Deeply negative

ROA

-60.22
Deeply negative

Business Description

Biomea Fusion is a US-based medical research company working to bring new treatments to people living with diabetes and obesity. Founded in 2017 and based in San Carlos, California, the company is developing pills that work by blocking a specific protein in the body to influence how cells grow and function. Its primary drug in development, icovamenib, is taken by mouth and targets a protein called menin, which plays a key role in regulating genes and cell activity.

Key Fundamentals

EPS-0.29
ROE-157
ROIC-862
ROA-60.22
EBITDA, mln-32.03
EV / EBITDA-0.38
EV / EBIT-0.37

Quote Details

Last 0.6395
Change 0.0167 (2.68%)
Open 0.63
Volume 1,096,790
Turnover 701,397
Average Volume 2,292,281

Financial Ratios

Leverage Ratio3.04
Current Ratio3.48
Price / Book3.78
Price / Tangible Book3.78
Debt / Equity0.07

Financial Strength

Piotroski F-Score 2 / 9
1-Year Target Price6.17
Short Ratio5.55
Short % of Float26.43

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 6.57% 90 / 100   
1 Month -50.81% 4 / 100   
2 Months -49.25% 9 / 100   
6 Months -53.32% 12 / 100   
1 Year -53.32% 17 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog